REGATTA-AF tests whether autonomic ablation can extend the reach of pulsed field PVI
A new randomized trial will ask a deceptively simple question in paroxysmal atrial fibrillation: does adding targeted radiofrequency ablation of the ganglionated plexi improve outcomes when pulmonary vein isolation is already being performed with pulsed electric field energy? The REGATTA-AF study is built around that issue, and its design reflects a growing recognition that electrical isolation alone may not fully address the autonomic triggers that help sustain AF recurrence.
The study will enroll 250 patients at three highly specialized centers in the Czech Republic and compare two strategies. One arm will receive pulsed electric field pulmonary vein isolation with roof line ablation alone; the experimental arm will add radiofrequency ganglionated plexi ablation. Investigators are not testing a small technical refinement. They are testing whether deliberate parasympathetic modulation can improve rhythm durability after a non-thermal ablation approach that already aims to reduce collateral injury.
Atrial fibrillation is often driven by the interplay between pulmonary vein ectopy and the autonomic nervous system. PVI targets the former. Ganglionated plexi ablation targets the latter. The logic is straightforward: if vagal inputs help initiate or perpetuate atrial fibrillation, then a lesion set that suppresses both pulmonary vein triggers and autonomic facilitation could produce more durable freedom from recurrence. PEF has changed the safety profile of ablation by offering a tissue-selective, non-thermal method for PVI, but its autonomic effect may be transient. REGATTA-AF is designed to determine whether that gap can be closed with adjunctive RF denervation.
This is a multicentre, randomized, single-blind superiority trial. Participants must have symptomatic, drug-refractory paroxysmal AF, with paroxysms that terminate spontaneously or with intervention within 7 days of onset and failure of at least one Class I-IV antiarrhythmic drug. Enrollment is limited to adults 30 to 65 years old, and the protocol excludes patients with persistent or permanent AF, marked left atrial enlargement, reduced left ventricular function, prior atrial ablation or surgery, autonomic dysfunction such as diabetic cardiac autonomic neuropathy, and other conditions that would confound the interpretation of a denervation strategy.
The primary endpoint is crisp: freedom from recurrent AF or atrial tachycardia lasting more than 30 seconds during 12 months of follow-up, excluding a 2-month blanking period, without Class I or III antiarrhythmic drugs. In practical terms, the study is not rewarding short-lived suppression. It is asking whether the rhythm result survives beyond the peri-procedural period and beyond pharmacologic rescue.
Why the autonomic signal matters in a PEF era
The biologic rationale sits at the center of the trial. PEF is valued because it can isolate pulmonary veins with a favorable safety profile and limited thermal spread. Yet the autonomic nervous system does not disappear when the veins are electrically boxed in. Ganglionated plexi around the atria can continue to influence refractoriness, conduction, and susceptibility to triggered activity. If those parasympathetic inputs remain active, a patient may still cycle back into AF even after apparently successful PVI.
That issue explains why the trial includes direct measures of cardiac autonomic function rather than relying only on arrhythmia recurrence. Investigators will assess acute vagal denervation with extracardiac vagal stimulation during the procedure, recording the longest P-P and R-R pauses before and after the last pulsed field application or radiofrequency application. They will also use atropine testing at baseline and 12 months to evaluate longer-term vagal denervation. A vagal atrial induction test will probe AF inducibility at baseline and again at the end of the procedure. These are mechanistic endpoints, but they also speak to bedside reality: if the autonomic substrate is altered, the rhythm outcome should change with it.
The secondary endpoints widen the lens. Quality of life will be tracked with the AFEQT questionnaire at baseline and 12 months. Safety will be measured through periprocedural complications and major adverse cardiac events over follow-up, including tamponade, stroke or TIA, major bleeding requiring intervention or transfusion, and vascular access complications requiring treatment. Those safety outcomes matter because any incremental lesion set must earn its place without eroding the procedural advantages that made pulsed field ablation attractive in the first place.
One sentence captures the trial’s central tension: a cleaner pulmonary vein lesion set may not be enough on its own.
Safety, durability, and the limits of lesion-based thinking
REGATTA-AF is also a test of workflow. The protocol proposes a combination strategy in an era when operators are increasingly drawn to non-thermal technologies for efficiency and tissue selectivity. If the added RF component improves freedom from recurrence without a meaningful safety penalty, the study could support a more tailored ablation sequence in paroxysmal AF. If the benefit is modest or absent, the result would argue that PEF PVI already captures most of the actionable substrate in this population, at least under the conditions selected here.
The inclusion criteria and exclusions are doing important scientific work. By narrowing the population to adults with drug-refractory symptomatic paroxysmal AF, the study reduces the noise created by more advanced atrial disease. The exclusion of patients with left atrial anteroposterior diameter of 50 mm or more and those with left ventricular ejection fraction below 40% further concentrates the cohort on a more favorable ablation substrate. That makes the findings easier to interpret, but it also means the results will speak most directly to a relatively selected group rather than the full spectrum of AF seen in routine practice.
The timing of the trial is also telling. Study start is estimated for April 2027, with primary completion projected for April 2028 and final completion for April 2029. For a field that has moved quickly into pulsed field technology, this kind of mechanistic superiority study will matter because it asks whether the next advance should be about energy source alone or about combining energy source with more deliberate autonomic targeting.
The trial is being sponsored by the Institute for Clinical and Experimental Medicine, with collaborators at Faculty Hospital Kralovske Vinohrady and University Hospital Olomouc. The official title is RadiofrEquency Ablation of Ganglionated Plexi Added to The Pulsed ElecTric Field Pulmonary Vein Isolation for PAroxysmal Atrial Fibrillation, or REGATTA-AF.
For clinicians, the most important question is not whether PVI works. It does. The question is whether autonomic denervation can make a non-thermal ablation strategy more durable without erasing the procedural advantages that made it appealing in the first place. REGATTA-AF was built to answer that exact question.
What the endpoint structure will reveal about AF recurrence
The study’s endpoint architecture should yield more than a binary positive-or-negative result. Freedom from recurrent AF or atrial tachycardia over 12 months will tell the main story, but the long-term vagal testing and arrhythmia inducibility assessments may reveal whether a rhythm benefit is mediated by genuine autonomic remodeling or by a narrower procedural effect around the time of ablation. If recurrence falls while vagal measures remain unchanged, the mechanism will need rethinking. If both move in parallel, the case for adjunctive GP ablation becomes biologically stronger.
There is also a practical implication for future ablation workflows. A strategy that improves rhythm control by targeting ganglionated plexi would move attention beyond the pulmonary veins themselves and toward the neural architecture that surrounds them. If the trial is negative, it will still have value: it would set a boundary on how much incremental benefit can be expected from adding RF denervation to PEF PVI in selected patients with paroxysmal AF.
- • ClinicalTrials.gov Trial Protocol (NCT07943013): https://clinicaltrials.gov/study/NCT07943013